<<

Update on Challenging Disorders of Pigmentation in of Color Heather Woolery-Lloyd, M.D. Director of Ethnic Voluntary Assistant Professor Miller/University of Miami School of Medicine Department of and Cutaneous Surgery What Determines Skin Color? What Determines Skin Color?

 No significant difference in the number of between the races  2000 epidermal melanocytes/mm2 on head and forearm  1000 epidermal melanocytes/mm2 on the rest of the body  differences present at birth

Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff,K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192-220, New York, NY: McGraw Hill in Black and White Skin

Black White

Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. Nature1969;222:1081-1082 Jimbow K, Quevedo WC, Prota G, Fitzpatrick TB (1999) Biology of melanocytes. In I. M. Freedberg, A.Z. Eisen, K. Wolff, K.F. Austen, L.A. Goldsmith, S. I. Katz, T. B. Fitzpatrick (Eds.), Dermatology in General Medicine 5th ed., pp192- 220, New York, NY: McGraw Hill Role of -Advantages

 Melanin absorbs and scatters energy from UV and visible light to protect epidermal cells from UV damage Disadvantages

or injury to the skin is almost immediately accompanied by alteration in pigmentation  Dyschromias

 Post-Inflammatory hyperpigmentation  Pigmentosus  Progressive Macular Hypomelanosis  Post Inflammatory Hyperpigmentation: Acne PIH from Acne

 Acne hyperpigmented macule  Patients are most concerned with pigmentation Not the acne!!! Pigment and Acne in Skin of Color Common Questions

 Does benzoyl peroxide bleach the skin? No Rarely can cause post-inflammatory hypopigmentation Post inflammatory hyperpigmentation more common Pigment and Acne in Skin of Color Common Questions  Does benzoyl peroxide cause hyperpigmentation in SOC? Yes if patient develops irritation Approximately 5% of the population is sensitive to BP Many can tolerate lower concentrations (less than 5%) Pigment and Acne in Skin of Color Common Questions

 Does minocycline cause hyperpigmentaion in SOC? Yes Clinically can see overall darkening of face Also reported darkening of lips, scars, legs Use other antibiotics as first line therapy in SOC Pigment and Acne in Skin of Color Common Questions

 Do cause hyperpigmentation in SOC? Yes if patient develops irritation More common with and tazarotene Less common with but still possible Usually occurs within a month of use Resolves once agent is discontinued Pigment and Acne in Skin of Color Common Questions

Do retinoids also treat hyperpigmentation? Yes Tretinoin Tazarotene Adapalene Tretinoin

 Influences transfer  Tretinoin 0.1% has been demonstrated to be effective for melasma in a vehicle- controlled trial  Slow results

Griffiths CE. Finkel LJ. Ditre et al.British Journal of Dermatology 1993; 129(4):415-21 Tretinoin for

 Blinded vehicle controlled trial  68 AA subjects with hyperpigmentation due to acne, , eczema, shaving irritation  40 weeks  Topical tretinoin 0.1% cream or vehicle applied to face and arms  Investigator assessments and colorimetry

La Voo EJ. New Eng J Med Nov 1993 Tretinoin for dyschromia

 Evaluated hyperpigmented and normal skin  Hyperpigmented skin  Improvement in affected skin seen clinically at  4 weeks with tretinoin vs 24 weeks with vehicle  Normal skin  No significant lightening observed clinically but mild skin lightening was observed via colorimetry in the tretinoin group

La Voo EJ. New Eng J Med Nov 1993 Tretinoin for dyschromia

Tretinoin 0.1% cream achieved more rapid clearance of hyperpigmented compared to vehicle 4 weeks vs 24 weeks

La Voo EJ. New Eng J Med Nov 1993 Patient with acne and hyperpigmentation treated with Tretinoin 0.1% cream

La Voo EJ. New Eng J Med Nov 1993 Tazarotene for PIH

 Blinded vehicle controlled trial  74 patients from darker racial ethnic groups who had acne  Once-daily application of tazarotene cream was shown to be effective against PIH  Reductions in overall PIH severity and in the intensity and area of hyperpigmentation was observed when compared to vehicle within 18 weeks (P< or =.05).

Grimes P. Callender V. Cutis. 77(1):45-50, 2006 Jan. Adapalene in Black Africans for PIH

 Open label trial of patents with acne  N=44  Identified 5 lesions on each patient and observed color change over 4 weeks  66% of patients experienced reductions in both number of hyperpigmented macules and density of the hyperpigmentation

Jacyk WK J Eur Acad Vener Dermatol Vol15 Suppl3 2001 Tazarotene vs Adapalene for PIH

 Blinded controlled trial n=180  Evaluated in improvement in acne and PIH  Demographics (Total “nonwhite” subjects=62%) Black 29% Asian 12% Hispanic 15% Other 6%

Tanghetti E et al J Drugs Dermatol. 2010 May;9(5):549-58 Tazarotene vs Adapalene

 Both tazarotene 0.1% cream and adapalene 0.3% gel were effective for acne  The percentage of non-white patients with compete resolution of their PIH at week 16  20 % (5/25) in the tazarotene 0.1% cream group  7% (2/29) in the adapalene 0.3% gel group  Tazarotene 0.1% cream was more effective than adapalene 0.3% gel in reducing PIH  Subjects experienced more , peeling, dryness and burning with tazarotene compared to adapalene

Tanghetti E et al J Drugs Dermatol. 2010 May;9(5):549-58 reduces hyperpigmentation in acne

 Ten black patients, ranging in age from 17 to 34 years, were treated for nodulocystic acne with 1 mg/kg/d of isotretinoin for 20 weeks  The authors concluded “isotretinoin is as safe and effective in the black patient with acne as it is in the white patient with acne”  An additional benefit in black patients was the prevention of new, and repression of old, post- inflammatory hyperpigmentation.

Kelly, A. Paul, and Darlene D. Sampson. "Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin." Journal of the National Medical Association 79.12 (1987): 1266. Before and after 20 weeks Isotretinoin 1mg/kg

Kelly, A. Paul, and Darlene D. Sampson. "Recalcitrant nodulocystic acne in black Americans: treatment with isotretinoin." Journal of the National Medical Association 79.12 (1987): 1266. Retinoids work for PIH in acne

 Don’t hesitate to use them in skin of color  Choose the one that best suits your patients needs! Acne and Post-Inflammatory Hyperpigmentation - Treatment

 Acne and dyschromia (<16yo)  Retinoids not only improve acne but also pigmentation  20% cream or 15% gel Works on hyperpigmentation and acne  with  Consider natural therapies (soy, licorice or emblica) Acne and Post-Inflammatory Hyperpigmentation

 Acne and dyschromia (>16yo)  Add  2% available OTC  4% available with a prescription  6-8% can be compounded  Apply only to the affected area as needed  Avoid continued long term use  Less than 2 months  Maintain with alternate therapies Hydroquinone Sensitivity

 A subset of patients are sensitive to and irritated by HQ  Irritation from HQ is frequently due to  HQ  sodium metabisulfite (a common preservative in HQ preparations)  Continuing HQ despite irritation can lead to post- inflammatory hyperpigmentation

Pei-Ying Huang, Chia-Yu Chu (2007) Allergic contact due to sodium metabisulfite in a bleaching cream 56 (2) , 123–124 Before treatment After 8 weeks of HQ8%/Tret0.025%/Dex0.1% Hydroquinone Halo

 Occurs when hydroquinone is applied with the fingertips  To avoid the hydroquinone halo  Advise patient not to rub HQ in with fingertips  Utilize cotton tipped applicator to spot treat  Apply HQ to dark spots first and then apply to full face Post-Inflammatory Hyperpigmentation- Summary

 Prevention is the best therapy  Remember post inflammatory hyperpigmentation can take an average of 4 months to clear Melasma Clinical Pearls in Hyperpigmentation -Focus on Melasma

Melasma Dialogue Treatment Plan Maintenance Plan Melasma Dialogue

• Just as important as the treatment plan • Patient must understand the natural course of melasma • Take time with new patients • Ask about meds (specifically- hormones) Melasma- Manage Expectations *What I tell every patient*

 “Melasma is a chronic condition”  “Disease of women in their 30’s, 40’s, and 50’s”  “Tends to resolve in later decades. You won’t have this forever”  “There is no one simple “cream or peel” that you use once to make it go away” BUT “There are many great treatments to keep your melasma under control” *Our Goal* Decrease Pigment Size and Intensity and Prevent Flares NO TREATMENT WITH TREATMENT/MANAGEMENT Treatment Plan

Sun avoidance and sun protection Treatment Phase Maintenance Phase Sun Avoidance and Sun Protection Sun Avoidance and Sun Protection

 Spend time to emphasize the importance of sun block and sun avoidance  In some ways this is more important than the treatment itself  “10 minutes of unprotected sun exposure and the melasma will come right back” Sun Avoidance and Sun Protection

 Broad Spectrum UVA/UVB Blocker  Add Visible light coverage if possible Look for that contain Iron Oxide Iron oxide is a pigment so color matching different skin types can be challenging  Add an oral agent UV-Visible Light Sunscreen vs UV only Sunscreen in Melasma

 68 patients with melasma were randomized in two groups to receive HQ 4 % plus either UV-VL sunscreen SPF ≥ 50 UV-only sunscreen SPF ≥ 50 8 weeks Assessed by Melasma Activity and Severity Index Colorimetry (L*) Histological analysis of melanin Castanedo‐Cazares, Juan Pablo, et al. "Near‐visible light and UV photoprotection in the treatment of melasma: a double‐blind randomized trial." Photodermatology, photoimmunology & photomedicine 30.1 (2014): 35-42. UV-Visible Light Sunscreen vs UV only Sunscreen in Melasma Improvement in UV-Visible light group showed 15% greater improvement over UV only sunscreen for MASI 28% greater improvement over UV only sunscreen for colorimetry (L*) 4% greater improvement over UV only sunscreen for melanin

Castanedo‐Cazares, Juan Pablo, et al. "Near‐visible light and UV photoprotection in the treatment of melasma: a double‐blind randomized trial." Photodermatology, photoimmunology & photomedicine 30.1 (2014): 35-42. Polypodium Leucotomos Oral Photoprotection

 Tropical fern plant  Antioxidant  Provides systemic photoprotection  Significant decrease in

 erythema

cells

 cyclobutane pyrimidine dimers

Middelkamp-Hup MA, Pathak MA, Parrado C et al. J Am Acad Dermatol. 2004 Dec;51(6):910-8. Woolery-Lloyd, Martin, Caperton, Poster AAD 2012 Polypodium Leucotomos

 Investigator Initiated, double blinded, placebo controlled  21 subjects, 12 weeks  PL 240 mg BID vs placebo pill BID  Both groups used sunscreen SPF 45  Patient Assessment Mild and Moderate Improvement  PL subjects- Mild Imp 50%, Moderate Imp 13%  Placebo subjects- Mild Imp 17%, Moderate Imp 0%  MELASQOL Improvement  59% of PL subjects  27% of placebo (p<0.05) Woolery-Lloyd, Martin, Caperton, Poster AAD 2012 Woolery-Lloyd, Martin, Caperton, Poster AAD 2012 Photos – Polypodium leucotomos

Baseline Week 12

Woolery-Lloyd, Martin, Caperton, Poster AAD 2012 Treatment Phase Treatment Phase

 Start with HQ for 1-2 months  Modified Kligman from compounding pharmacy Hydroquinone 8%/Tretinoin 0.025%/ Dexamethasone 0.1%  Emphasize the importance of hydroquinone holidays Why? – Because the effect of HQ plateaus over time The longer the time periods between HQ the better Goal 2-3 courses per year at the most Treatment Phase - Clinical Pearl

 Add 2.5% cream at night for the first month and then as needed after excessive sun exposure  Why add a ? Multiple studies to support the use of fluorinated in melasma Hydrocortisone 2.5% may offer some benefit without unwanted side effects Most importantly - may reduce any irritation caused by the modified Kligman formula  Tell patient to stop HQ if any redness or irritation Maintenance Phase: The Hydroquinone Holiday Maintenance Phase

 This is actually the most challenging aspect of treating melasma  Maintain with a hydroquinone free skin brightener  May need to rotate products  Only use HQ as needed  4-6 weeks a few times a year  Use hydrocortisone 2.5% cream at night as needed after any excessive sun exposure  Keep emphasizing sun block and sun avoidance  Patients who practice strict sun avoidance are the most successful Hydroquinone Alternatives

Open label & Animal Studies Blinded Controlled Trials  Arbutin/Deoxyarbutin  Soy  Aloesin   Kojic Acid  Licorice Extract

 Linoleic acid/alpha linoleic  Vitamin C acid/oleic acid  Niacinamide  Ellagic acid  Azelaic Acid

 Acerola fruit extract  Lignin Peroxidase

 Methimazole  Phenylethyl resorcinol transaminic acid, tetrapeptides, niacinamide, plankton  Dioic Acid extracts, marine extracts, polysaccharides  Tranexamic acid  Hydroxyphenoxyproprionic acid, ellagic acid, yeast, combination

 N-acetylglucosamine-split face  Decapeptide -12  Kojic Acid/Emblica Sample regimen-Treatment Phase

 AM  Cleanse  Antioxidant with Skin brightener  Broad Spectrum UVA/UVB/VL PLUS Oral Antioxidant  PM  Cleanse  HQ 8%/ Tretinoin 0.025%/ Dexamethasone 0.1% ( 4-8 weeks)  Hydrocortisone 2.5% (4 weeks)  Moisturizer if needed Sample regimen-Maintenance Phase

 AM  Cleanse  Antioxidant with skin brightener  Broad Spectrum UVA/UVB/VL PLUS Oral Antioxidant  PM  Cleanse  HQ free skin brightener (ex: azelaic acid)  Hydrocortisone 2.5% (as needed if excessive sun exposure)  Moisturizer if needed Clinical Pearls for Challenging Cases

 Add oral photoprotection  Add Hydrocortisone 2.5% cream for 1 month while using a high concentration HQ and after any excessive sun exposure  Add visible light photoprotection if possible  Consider adding monthly chemical peels and micro- needling  Set expectations so that the patient understands the natural course of melasma Lichen Planus Pigmentosus Lichen planus pigmentosus

 Starts in the third or fourth decade of life  Slight female predilection  Lesions initially appear as small, ill-defined oval to round macules, which later become confluent to form large areas of pigmentation  Pigmentation in different patients varies from slate grey to brownish-black Lichen planus pigmentosus Lichen planus pigmentosus

 Common diagnosis in India Constituted 4.1% (124 ⁄ 3020) of patients referred to the pigmentary clinic  In earlier reported series, pruritus was present in 50% to 62%  May also have associated LP or FFA

Kanwar, A. J., et al. "A study of 124 Indian patients with lichen planus pigmentosus." Clinical and experimental dermatology28.5 (2003): 481-485. New onset dermal pigmentation on the neck present for 4 months Lichen planus pigmentosus

 “LPP probably represents a lichenoid reaction to an unknown agent or stimuli”  Treatment is challenging  Prednisone  Topical steroids  /  Glycolic acid  Azelaic acid

Kanwar, A. J., et al. "A study of 124 Indian patients with lichen planus pigmentosus." Clinical and experimental dermatology28.5 (2003): 481-485. Drug Induced Hyperpigmentation Drug Induced facial hyperpigmentation

 Common in African American population  Clinically dark brown hyperpigmentation on the face (not slate grey)  Most common cause is HCTZ Drug Induced facial hyperpigmentation

 Consider switching to BP med that is not photosensitizing  Start HC 2.5% cream and a HQ free skin brightener Drug Induced facial hyperpigmentation

BP drugs that don’t cause BP drugs associated with photosenitivity photosensitivity  Atenolol  Metoprolol

 Labetalol  All ace inhibitors

 Angiotensin receptor blocker  Thiazide except losartan  Bumetanide  Clonidine  Lasix  Amlodipine  Diltiazem  Verapamil  Losartan Stopped HCTZ and used Moisturizer/Sunscreen with Soy Daily

June 2007 June 2008

Progressive Macular Hypomelanosis

 First described in 1988 by Guillet in Martinique  Observed asymptomatic hypopigmented macules on the trunk of young women of mixed racial background  Progressive slow course

Guillet G. Helenon R. Gauthier Y. Surleve-Bazeille JE. Plantin P. Sassolas B. Progressive macular hypomelanosis of the trunk: primary acquired hypopigmentation. Journal of Cutaneous Pathology. 15(5):286-9, 1988 Oct Relyveld GN. Menke HE. Westerhof W. Progressive macular hypomelanosis: an overview. American Journal of Clinical Dermatology. 8(1):13-9, 2007 Perman M. Sheth P. Lucky AW. Progressive macular hypomelanosis in a 16-year old. Pediatric Dermatology. 25(1):63-5, 2008 Jan-Feb Progressive Macular Hypomelanosis

Differential diagnosis includes extensive alba and Differs histologically and clinically

Relyveld GN. Menke HE. Westerhof W. Progressive macular hypomelanosis: an overview. American Journal of Clinical Dermatology. 8(1):13-9, 2007 Progressive Macular Hypomelanosis Etiology  Propionibacterium acnes bacteria in hair follicles are the cause of PMH as a result of production of a hypothetical depigmenting factor  Red follicular in the hypopigmented spots and the absence of this phenomenon in normal skin when examined under a Wood's light in a dark room  Cultivation of P. acnes from the follicles in the hypopigmented spots but not from follicles in normal-looking skin  Improvement with topical antimicrobial treatment in combination with UVA light

Relyveld GN. Menke HE. Westerhof W. Progressive macular hypomelanosis: an overview. American Journal of Clinical Dermatology. 8(1):13-9, 2007 Westerhof W. Relyveld GN. Kingswijk MM. de Man P. Menke HE. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Archives of Dermatology. 140(2):210-4, 2004 Feb Progressive Macular Hypomelanosis Etiology

from lesional skin of 8 women demonstrated gram-positive bacteria in the pilosebaceous duct, and a mild perifollicular lymphocytic infiltrate was seen  7/8 cultured biopsy specimens grew P. acnes in affected skin  No bacteria identified in normal skin  histology and culture negative  Proposed that these strains of P acnes may produce a factor that interferes with melanogenesis

Westerhof W. Relyveld GN. Kingswijk MM. de Man P. Menke HE. Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis. Archives of Dermatology. 140(2):210-4, 2004 Feb Progressive Macular Hypomelanosis- Wood’s Lamp P Acnes strains (PMH 5 and PMH7) Progressive Macular Hypomelanosis Treatment

Combination therapy with clindamycin and benzoyl peroxide UVA three times a week for a period of 12 weeks NBUVB Oral doxycycline Chung YL. Goo B. Chung WS. Lee GS. Hann SK. A case of progressive macular hypomelanosis treated with narrow- band UVB. Journal of the European Academy of Dermatology & Venereology. 21(7):1007-9, 2007 Aug. Progressive Macular Hypomelanosis Treatment

 UVA plus benzoyl peroxide 5% gel QAM and clindamycin 1% lotion QHS vs UVA plus fluticasone  45 patients  26 week randomized within-patient left-right comparison study  Repigmentation rate  62% benzoyl peroxide/clindamycin/UVA side  22% fluticasone/UVA side  p <0.0001

Relyveld GN. Menke HE. Westerhof W. Progressive macular hypomelanosis: an overview. American Journal of Clinical Dermatology. 8(1):13-9, 2007 After 3 months of Before Benzoyl Peroxide 4% wash and Clindamycin lotion Vitiligo Vitiligo

 1-2 percent of the world's population  Over 40 million people are affected  Affects all races  More noticeable in people of color Vitiligo-Work Up

 Ask about family history of  Do autoimmune work up  ANA/ antibodies  NALP1 is the gene associated with vitiligo and autoimmune

N Engl J Med. 2007 Mar 22;356(12):1216-25 Vitiligo-Treatment

 Topical steroids  Intermittent treatment with Class I steroid for 1-2 weeks can be very effective  Topical Immunomodulators  Tacrolimus and Pimecrolimus  Oral antioxidants/vitamins  NB-UVB  Age dependent

Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol 1997;77:460 Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995;190:223 Vitiligo

 Topical tacrolimus is effective  Works best on the face  Combine with 10 minutes of sunlight/day  Twice daily application is most effective

Radakovic S. Breier-Maly J. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. Journal of the European Academy of Dermatology & Venereology. 23(8):951-3, 2009 Aug. Grimes PE. Soriano T. Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. Journal of the American Academy of Dermatology. 47(5):789-91, 2002 Nov. Vitiligo-Coverage

 Coverage makeup  Dermablend/Covermark

 Waterproof/smudge resistant  Dyoderm or VitaDye

 Stain  Mineral Makeup

 Contains zinc oxides, titanium dioxide, iron oxides

 Offers sun protection SPF 15-30  Cover FX Coverage Make Up Vitiligo

Support Groups National Vitiligo www.nvfi.org Thank You!